These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12712786)

  • 1. Use of oral and implantable naltrexone in the management of the opioid impaired physician.
    Hulse GK; O'Neil G; Hatton M; Paech MJ
    Anaesth Intensive Care; 2003 Apr; 31(2):196-201. PubMed ID: 12712786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants.
    Hulse GK; Tait RJ; Comer SD; Sullivan MA; Jacobs IG; Arnold-Reed D
    Drug Alcohol Depend; 2005 Sep; 79(3):351-7. PubMed ID: 15899557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.
    Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Yaroslavtseva T; Pecoraro A; Woody G
    Am J Drug Alcohol Abuse; 2016 Sep; 42(5):614-620. PubMed ID: 27436632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone implants -- duration, tolerability and clinical usefulness. A pilot study.
    Waal H; Frogopsahl G; Olsen L; Christophersen AS; Mørland J
    Eur Addict Res; 2006; 12(3):138-44. PubMed ID: 16778434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
    Hulse GK; Morris N; Arnold-Reed D; Tait RJ
    Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The use of different forms of naltrexone in the treatment of opioid dependence].
    Krupitskiĭ EM; Zvartau EE; Blokhina EA; Woody G
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(11 Pt 2):66-72. PubMed ID: 22611701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?
    Nunes EV; Rothenberg JL; Sullivan MA; Carpenter KM; Kleber HD
    Am J Drug Alcohol Abuse; 2006; 32(4):503-17. PubMed ID: 17127538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circumstances of death of opioid users being treated with naltrexone.
    Darke S; Farrell M; Duflou J; Larance B; Lappin J
    Addiction; 2019 Nov; 114(11):2000-2007. PubMed ID: 31278812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naltrexone implants.
    Warhaft N
    Anaesth Intensive Care; 2003 Oct; 31(5):592-3. PubMed ID: 14601290
    [No Abstract]   [Full Text] [Related]  

  • 10. A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.
    Kelty E; Hulse G
    Drugs; 2017 Jul; 77(11):1199-1210. PubMed ID: 28536980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence.
    Larney S; Gowing L; Mattick RP; Farrell M; Hall W; Degenhardt L
    Drug Alcohol Rev; 2014 Mar; 33(2):115-28. PubMed ID: 24299657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naltrexone implant treatment for buprenorphine dependence--Mauritian case series.
    Jhugroo A; Ellayah D; Norman A; Hulse G
    J Psychopharmacol; 2014 Aug; 28(8):800-3. PubMed ID: 24695742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained-release naltrexone: novel treatment for opioid dependence.
    Comer SD; Sullivan MA; Hulse GK
    Expert Opin Investig Drugs; 2007 Aug; 16(8):1285-94. PubMed ID: 17685876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naltrexone in addicted business executives and physicians.
    Washton AM; Pottash AC; Gold MS
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):39-41. PubMed ID: 6088468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of oral naltrexone for treating opioid-dependent offenders.
    Coviello DM; Cornish JW; Lynch KG; Alterman AI; O'Brien CP
    Am J Addict; 2010; 19(5):422-32. PubMed ID: 20716305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retention in naltrexone implant treatment for opioid dependence.
    Kunøe N; Lobmaier P; Vederhus JK; Hjerkinn B; Hegstad S; Gossop M; Kristensen O; Waal H
    Drug Alcohol Depend; 2010 Sep; 111(1-2):166-9. PubMed ID: 20570059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges to antagonist blockade during sustained-release naltrexone treatment.
    Kunøe N; Lobmaier P; Vederhus JK; Hjerkinn B; Gossop M; Hegstad S; Kristensen Ø; Waal H
    Addiction; 2010 Sep; 105(9):1633-9. PubMed ID: 20707781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
    Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonist Models for Relapse Prevention and Reducing HIV Risk.
    Woody GE; Krupitsky E; Zvartau E
    J Neuroimmune Pharmacol; 2016 Sep; 11(3):401-7. PubMed ID: 26922659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone.
    Sullivan MA; Bisaga A; Glass A; Mishlen K; Pavlicova M; Carpenter KM; Mariani JJ; Levin FR; Nunes EV
    Drug Alcohol Depend; 2015 Feb; 147():122-9. PubMed ID: 25555621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.